Investigating stress markers during meth treatment in HIV-positive individuals

Expression of Stress Markers in MSM Living With HIV Receiving Contingency Management for Methamphetamine Use Disorder

This study is testing how methamphetamine use affects health markers in HIV-positive individuals assigned male at birth who are either getting treatment for their drug use or not using substances at all.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 55 (estimated)
• Ages: 18 Years to 45 Years
• Sex: Male
• Sponsor: University of California, Los Angeles (Academic / other)
• Locations: 1 site (Los Angeles, California)
• Trial ID: NCT05558345 on ClinicalTrials.gov

What this trial studies

This trial examines the relationship between inflammatory markers and methamphetamine use in HIV-positive individuals assigned male at birth. It involves two groups: one receiving contingency management for methamphetamine use disorder and a control group of non-substance users. Over 12 weeks, participants will be monitored for changes in drug use and viral load, with assessments conducted twice weekly. The study aims to provide insights into how methamphetamine use impacts health markers in this population.

Who should consider this trial

Good fit: Ideal candidates are HIV-positive individuals assigned male at birth, aged 18 to 45, who either have methamphetamine use disorder or are non-substance users.

Not a fit: Patients who are not HIV-positive or do not meet the specific criteria for methamphetamine use disorder may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved treatment strategies for HIV-positive individuals with methamphetamine use disorder.

How similar studies have performed: Other studies have shown promise in using contingency management for substance use disorders, indicating potential for success in this approach.

Eligibility criteria

Inclusion Criteria:

For Contingency Management:

1. Assigned male sex at birth
2. 18 to 45 years of age
3. Reports having sex with men in the past 12 months.
4. HIV-positive (confirmed by certification or by HIV rapid test)
5. Has an HIV care provider (last seen in the past 12 months)
6. Has a current antiretroviral prescription
7. Meets the DSM-5 criteria for methamphetamine use disorder using SCID-5
8. Urine test is positive for methamphetamine within 30 days of their screening visit
9. Seeking treatment for methamphetamine use disorder.
10. Ability to attend twice weekly appointments for drug testing and treatment

For Non-substance-using Control:

1. Assigned male sex at birth
2. 18 to 45 years of age
3. Reports having sex with men in the past 12 months.
4. HIV-positive (confirmed by certification or by HIV rapid test)
5. Has an HIV care provider (last seen in the past 12 months)
6. Has a current antiretroviral prescription

Exclusion Criteria:

For Contingency Management:

1. Identifies as (cis- or transgender) female
2. Reports another current or past substance use disorder
3. Reports being in another intervention or clinical trial for substance use
4. Positive test for opioids, cocaine, and/or MDMA

For Non-substance-using Control:

1. Identifies as (cis- or transgender) female
2. Positive test for methamphetamine, opioids, cocaine, and/or MDMA.
3. Reports substance use (methamphetamine, opioids, cocaine, MDMA, hallucinogens, heavy alcohol use, and/or tobacco) in the past 6 months
4. Reports past or current substance use disorder

Where this trial is running

Los Angeles, California

• UCLA Vine Street Clinic — Los Angeles, California, United States (Recruiting)

Study contacts

• Principal investigator: Michael J Li, PhD — UCLA Department of Family Medicine
• Study coordinator: Michael J Li, PhD

Conditions Substance-Related Disorders; HIV